Although we utilized two NSCLC cell lines with different EGFR status, additional cell lines with different molecular features should be tested to confirm the universality of involvement of the FGFR pathway in the development of pemetrexed resistance in lung cancer. This evidence concerns the gene EGFR and non-small cell lung carcinoma.